SCHEMBL4383397

SCHEMBL4383397

COc1cc2c(Nc3ccc4[nH]ccc4c3)ncnc2cc1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 8/20 0.70
EGFR P00533 10/20 0.66
ERBB2 P04626 1/20 0.66
KDR P35968 7/20 0.64
KIF5B P33176 4/20 0.64
RIPK2 O43353 2/20 0.60
JAK3 P52333 2/20 0.60
GAK O14976 1/20 0.60
STK10 O94804 1/20 0.60
FLT3 P36888 1/20 0.60
AAK1 Q2M2I8 1/20 0.60
Q6ZSR9 Q6ZSR9 1/20 0.60
SLK Q9H2G2 1/20 0.60
IRAK4 Q9NWZ3 1/20 0.60
RPS6KA6 Q9UK32 1/20 0.60
ALK Q9UM73 1/20 0.60
LCK P06239 3/20 0.58
ABCG2 Q9UNQ0 2/20 0.57
ABCB1 P08183 1/20 0.57
NOD1 Q9Y239 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4377353 0.99 RET (0.69) RETEGFRERBB2KDRKIF5B
SCHEMBL4376291 0.92 RET (0.84) RETEGFRERBB2KDRKIF5B
SCHEMBL8561433 0.91 RET (0.83) RETEGFRERBB2KDRKIF5B
Hydrochloric Acid SCHEMBL8904802 0.90 RET (0.81) RETEGFRERBB2KDRKIF5B
Hydrochloric Acid SCHEMBL8976571 0.86 RET (0.69) RETEGFRERBB2KDRKIF5B
SCHEMBL7976800 0.85 RET (0.70) RETEGFRERBB2KDRKIF5B
SCHEMBL4374268 0.84 EGFR (0.64) RETEGFRKDRKIF5BRIPK2
SCHEMBL4371491 0.84 RET (0.74) RETEGFRERBB2KDRGAK
SCHEMBL7982775 0.83 RET (0.67) RETEGFRERBB2KDRKIF5B
SCHEMBL2063370 0.83 EGFR (0.56) RETEGFRERBB2KDRRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 EP disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 US disclosed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 US disclosed
EP-1553097-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE AstraZeneca AB (SE) 2005-07-13 EP disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR RET 637/4885EGFR 500/4885ERBB2 1869/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 RET 1047/4885EGFR 549/4885ERBB2 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.